Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity

Blood

Volumn 119, Issue 2, 2012, Pages 368-376

  Nagai, Kozo ^a   Ochi, Toshiki ^a   Fujiwara, Hiroshi ^a,b   An, Jun ^a   Shirakata, Toshiaki ^a   Mineno, Junichi ^c   Kuzushima, Kiyotaka ^d   Shiku, Hiroshi ^e   Melenhorst, J Joseph ^f   Gostick, Emma ^g   Price, David A ^g   Ishii, Eiichi ^a   Yasukawa, Masaki ^a,b  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b EHIME UNIVERSITY   (Japan)

^c TAKARA BIO INC   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^g CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; AURORA A KINASE; HLA A ANTIGEN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FLOW CYTOMETRY; GENE EXPRESSION; GENE TRANSFER; HEMATOPOIETIC STEM CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TUMOR XENOGRAFT;

EID: 84855830623     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-360354     Document Type: Article

References (49)

1. Marumoto T, Zhang D, Saya H. Aurora-A-a guardian of poles. Nat Rev Cancer. 2005;5(1):42-50.
2. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003;4(11):842-845.
3. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998;17(11):3052-3065. (Pubitemid 28254378)
4. Gautschi O, Heighway J, Mack PC, Pumell PR, Lara PN Jr, Gandara DR. Aurora kinases as an anticancer targets. Clin Cancer Res. 2008;14(6): 1639-1648.
5. Ikezoe T, Yang J, Nishioka C, et al. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther. 2007; 6(6):1851-1857. (Pubitemid 46954062)
6. Ochi T, Fujiwara H, Suemori K, et al. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood. 2009;113(1):66-74.
7. Ewart-Toland A, Briassouli P, de Koning JP, et al. Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet. 2003;34(4):403-412. (Pubitemid 36935333)
8. Xu HT, Ma L, Qi FJ, et al. Expression of serine threonine kinase 15 is associated with poor differentiation in lung squamous cell carcinoma and adenocarcinoma. Pathol Int. 2006;56(7):375-380. (Pubitemid 43886801)
9. Boss DS, Beijnen JH, Schellens JH. Clinical experience with aurora kinase inhibitors: a review. Oncologist. 2009;14(8):780-793.
10. Dees EC, Infante JR, Cohen RB, et al. Phase 1 study of MLN8054, a selective inhibitor of AuroraA kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011;67(4):945-954.
11. Steeghs N, Eskens FA, Gelderblom H, et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol. 2009;27(30):5094-5101.
12. Traynor AM, Hewitt M, Liu G, et al. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011;67(2):305-314.
13. Hamada M, Yakushijin Y, Ohtsuka M, Kakimoto M, Yasukawa M, Fujita S. Aurora2/BTAK/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non-Hodgkin's lymphoma. Br J Haematol. 2003;121(3):439-447. (Pubitemid 36628335)
14. Kobayashi H, Azumi M, Hayashi S, et al. Characterization of human CD4 helper T cell responses against Aurora kinase A. Cancer Immunol Immunother. 2010;59(7):1029-1039.
15. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314(5796):126-129. (Pubitemid 44547756)
16. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009; 114(3):535-546.
17. Bendle GM, Linnemann C, Hooijkaas AI, et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med. 2010;16(5):565-570.
18. Okamoto S, Mineno J, Ikeda H, et al. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res. 2009; 69(23):9003-9011.
19. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917-924.
20. Calogero A, Hospers GA, Krüse KM, et al. Retargeting of a T cell line by anti MAGE-3/HLA-A2 alpha beta TCR gene transfer. Anticancer Res. 2000;20(3A):1793-1799. (Pubitemid 30628203)
21. Price DA, Brenchly JM, Ruff LE, et al. Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med. 2005;202(10):1349-1361. (Pubitemid 41668738)
22. Kuzushima K, Hayashi N, Kimura H, Tsurumi T. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8+ T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood. 2001;98(6):1872-1881.
23. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000;95(1):286-293. (Pubitemid 30017254)
24. Tsuji T, Yasukawa M, Matsuzaki J, et al. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood. 2005;106(2):470-476. (Pubitemid 40981240)
25. Folch G, Scaviner D, Contet V, Lefranc MP. Protein displays of the human T cell receptor alpha, beta, gamma and delta variable and joining regions. Exp Clin Immunogenet. 2000;17(4):205-215.
26. Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics. 1995;42(6):455-500. (Pubitemid 26025063)
27. Jedema I, van der Werff NM, Barge RM, Willemze R, Falkenburg JH. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood. 2004;103(7):2677-2682. (Pubitemid 38393024)
28. + cytotoxic T lymphocytes in humans. Blood. 2000;95(7):2352-2355.
29. Ito M, Hiramatsu H, Kobayashi K, et al. NOD/ SCID/gamma(c) (null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100(9):3175-3182. (Pubitemid 35217065)
30. Xue SA, Gao L, Hart D, at al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood. 2005;106(9):3062-3067. (Pubitemid 41565901)
31. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol. 2004; 172(1):104-113. (Pubitemid 38020461)
32. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13(18 Pt 1):5426-5435. (Pubitemid 47510370)
33. Hollyman D, Stefanski J, Przybylowski M, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009;32(2): 169-180.
34. Wang J, Press OW, Lindgren CG, et al. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther. 2004;9(4):577-586. (Pubitemid 38578808)
35. James SE, Greenberg PD, Jensen MC, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008;180(10):7028- 7038.
36. Hombach A, Muche JM, Gerken M, et al. T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30+ cutaneous lymphoma cells. Gene Ther. 2001;8(11):891-895. (Pubitemid 32577194)
37. Hudecek M, Schmitt TM, Baskar S, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1- specific chimeric antigen receptor. Blood. 2010; 116(22):4532-4541.
38. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112(6):2261-2271.
39. Offringa R. Antigen choice in adoptive T-cell therapy of cancer. Curr Opin Immunol. 2009; 21(2):190-199.
40. Moore AS, Blagg J, Linardopoulos S, Pearson ADJ. Aurora kinase inhibitors: novel small molecules with promising activity in acute and Philadelphia- positive leukemias. Leukemia. 2010;24: 671-678.
41. +blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop. 2009;2(1):2-8.
42. Misaghian N, Ligresti G, Steelman LS, et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia. 2009;23(1):25-42.
43. Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009; 5(1):31-42.
44. Kikushige Y, Shima T, Takayanagi S, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010; 7(6):708-717.
45. Saito Y, Kitamura H, Hijikata A, et al. Identification of therapeutic targets for quiescent, chemotherapy- resistant human leukemia stem cells. Sci Transl Med. 2010;2(17):17ra9.
46. Ochi T, Fujiwara H, Okamoto S, et al. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs show marked antileukemia reactivity and safety. Blood. 2011;118(6):1495-1503.
47. Morris EC, Tsallios A, Bendle GM, Xue SA, Stauss HJ. A critical role of T cell antigen receptor- transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci U S A. 2005;102(22):7934-7939. (Pubitemid 40781041)
48. + T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol. 2010;136(3):338-347.
49. Ly LV, Sluijter M, Versluis M, et al. Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res. 2010;70(21):8339-8346.